ProShares Trust - ProShares UltraPro QQQ 3x Shares
TQQQ
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $37.19 Billion |
|---|---|
| Enterprise Value | $37.01 Billion |
| Dividend Yield | $0.38 (0.56%) |
| Earnings per Share | $- |
| Beta | 3.96 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2834.16 |
| Enterprise Value to EBIT | -492.37 |
| Enterprise Value to Net Income | -525 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 12.0000▲ 1081.57% |
|---|---|
| Total Calls | 100▼ 100.00% |
| Total Puts | 1,200▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.28%▼ 3.49% |
|---|---|
| Total Invested | $121.58M▼ 84.46% |
| Investors Holding | 73▼ 269.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
This is a powerful committee controlling taxation and entitlement spending (like Medicare drug pricing), which would directly impact BioAge Labs' future revenues and profitability upon commercialization.
This committee directly regulates the FDA, which is the primary approval body for BioAge Labs' drug candidates, and influences NIH funding for health research, making it highly relevant.
This committee's oversight of intellectual property (patents) and antitrust laws is critical for biopharmaceutical companies, directly impacting their core assets and potential M&A activities.